Fátima Marín

Researcher at Hereditary Cancer group. IDIBELL

[Prof. Nikolai Slavov @slavov_n]

bioRxiv has a dedicated section for negative results.

Use it.

Share negative results.
Your colleagues will appreciate it.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies https://t.co/32y0IuHnla
@jcastilloiturra @mariapellise1 @MoreiraR_Leti @merydacaalvarez @MartaPinedaRiu @frankbalaguer @hospitalclinic @idibell_cat

[La Marató de 3Cat @la_marato]

La síndrome de Lynch augmenta el risc de tenir càncer d'endometri. La recerca que lidera Gabriel Capellà, de l'@ICO_oncologia - @idibell_cat, vol personalitzar la prevenció d'aquest càncer mitjançant l'empoderament de la dona en la presa de decisions dels tractaments

[Fátima Marín @FatimaMarinn]

🚨𝗪𝗲 𝗮𝗿𝗲 𝗵𝗶𝗿𝗶𝗻𝗴!
We are looking for a #bioinformatician to join our group at @idibell_cat! Work with NGS & omic analyses. More about us: https://t.co/by76D6qeNw
➡️ Collaborative research
➡️ Projects in hereditary cancer

‼️Info & applications👇
https://t.co/mARPmrhlvt

[Marta Pineda @MartaPinedaRiu]

We are hiring! Looking for a postdoctoral researcher to work on pancreatic cancer modelling. A joint collaboration between https://t.co/KIGFd5EPEb and https://t.co/USV4TBxPI1 @idibell_cat
Job application link: https://t.co/1FEurN1B4E

[Fátima Marín @FatimaMarinn]

A comprehensive analysis of series of patients with CMMRD-associated lymphomas collected through international collaboration.
https://t.co/c4YWTy37oV

[IDIBELL @idibell_cat]

Researchers develop and optimize the hs-MSI genetic test🧬, which will improve #CMMRD diagnosis, a rare cancer predisposition in children. This tool will also help refine their clinical prognosis, making them candidates to #immunotherapy

Read more 👉 https://t.co/LhOP3d50Jk

[Hamzeh Kay @hamkay02]

How do mismatch repair-deficient (MMRd) cancers trade off the evolutionary costs and benefits of elevated mutation rates?

Delighted to share our paper on adaptive mutability in MMRd colorectal cancer (CRC) @NatureGenet

https://t.co/BxUtYR1JEm

Tweetorial 🧵below

[Barbara Rivera @BRivera_Polo]

I am SUPER thrilled to announce that we have launched the Network for Rare Tumors of the Ovary website!!! A community meeting point for Patients, Researchers, Advocates and Clinicians interested in Rare Ovarian Tumors like SCCOHT and SCSTs. The NRTO explained in a thread:

[Marta Pineda @MartaPinedaRiu]

#InSiGHT2024 in Barcelona has just finished. We have had really good science and fun!
Very proud of @FatimaMarinn and @elisabetmunte presentations on CMMRD in Spain and open-source PMS2 pipeline.
See you all in Singapore!
@idibell_cat @ICO_oncologia

[Asad Naveed @dr_asadnaveed]

Harvard is offering free research courses.

No fees are required.

Here are 9 courses you don't want to miss:

[Clinical Chemistry @Clin_Chem_ADLM]

🔥 Highly sensitive microsatellite instability assay is a robust ancillary test for Constitutional Mismatch Repair Deficiency diagnosis, able to distinguish PMS2 biallelic carriers. @idibell_cat @ICO_oncologia @MartaPinedaRiu @FatimaMarinn
#MedTwitter
👇 https://t.co/ZZ8VyGZ2WY

[Marta Pineda @MartaPinedaRiu]

Very happy to share with you our last publication on CMMRD! Thank you very much to Fátima Marín, Julia Canet-Hermida and our great collaborators!
#hereditarycancer #CMMRD @Uri_Tabori @ICO_oncologia @idibell_cat